Polymorphism in matrix metalloproteinase gene promoters: Implication in regulation of gene expression and susceptibility of various diseases

Matrix Biology

Volumn 19, Issue 7, 2000, Pages 623-629

  Ye, Shu ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aneurysm; Atherosclerosis; Cancer; Gene promoter; Genetic polymorphism; Matrix metalloproteinase; Transcription

Indexed keywords

MATRIX METALLOPROTEINASE; SCLEROPROTEIN;

ALLELE; ANEURYSM; ARTHRITIS; ATHEROSCLEROTIC PLAQUE; CANCER; CANCER INVASION; CARTILAGE DEGENERATION; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; GENE EXPRESSION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HUMAN; METASTASIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; REVIEW;

EID: 0033742833     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0945-053X(00)00102-5     Document Type: Short Survey

References (58)

1. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor
2. Transcriptional repression of the human collagenase-1 (MMP-1) gene in MDA231 breast cancer cells by all-trans-retinoic acid requires distal regions of the promoter
3. Matrix metalloproteinases: a review
4. Identification of a cytokine-induced repressor of interleukin-1 stimulated expression of stromelysin 1 (MMP-3)
5. Impaired wound contraction in stromelysin-1-deficient mice
6. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia
7. A DNA polymorphism discovery resource for research on human genetic variation
8. Acute coronary thrombosis - the role of plaque disruption and its initiation and prevention
9. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis
10. Epidermal expression of collagenase delays wound-healing in transgenic mice
11. Regulation of matrix metalloproteinase gene expression
12. Structure and expression of the human gene for the matrix metalloproteinase matrilysin
13. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques
14. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects
15. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization
16. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial
17. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients
18. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease
19. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer
20. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes
21. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region
22. Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene
23. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases
24. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease
25. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease
26. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
27. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis
28. Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery
29. Metalloproteinases and their inhibitors in matrix remodeling
30. Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms
31. Extracellular matrix degradation
32. Stromelysins 1 and 2
33. Matrix metalloproteinases
34. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis
35. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease
36. Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis
37. Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm
38. Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm
39. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription
40. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation
41. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene
42. Characterization of a dinucleotide repeat in the 92 kDa type IV collagenase gene (CLG4B), localization of CLG4B to chromosome 20 and the role of CLG4B in aortic aneurysmal disease
43. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis
44. Apolipoprotein E and Alzheimer disease
45. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction
46. Plasma concentration of matrix metalloproteinase 9 in gastric cancer
47. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site
48. The matrix metalloproteinase family
49. Genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis
50. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression
51. Human stromelysin gene promoter activity is modulated by transcription factor ZBP-89
52. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms
53. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery
54. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1
55. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis
56. Elevated plasma stromelysin levels in arthritis
57. Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity
58. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications